AI in Drug Discovery: Novo Nordisk Speeds Up Drug Launches
Since Artificial Intelligence (AI) came into the picture, developments in the field of drug discovery have been dramatic. Day by day, a new innovation emerges. Companies are integrating AI to speed up processes and bring products to market sooner. Earlier, the race in pharma was about launching drugs first. Now, with AI in Drug Discovery, companies are focusing on staying ahead longer with faster, smarter, and more accurate drug development. To this end, Novo Nordisk plans to increase the use of AI to bring new medicines to patients soon. AI in Drug Discovery is a current trend influencing companies’ research and development.
AI is Changing the Way Medicines Reach Patients
The entire world knows that developing and launching a new medicine is a long and complex process. Even when clinical trials are successful, getting through regulatory compliance, safety data review, and launch planning is tedious. For the patients, it is an ever-waiting task. But the integration of AI has changed the course of this.
Danish pharma giant Novo Nordisk is increasing the use of AI in Drug Discovery and Development to handle these tasks effectively. According to scientists and company executives, the technology is already helping to frame regulatory paperwork, study safety reports, and support commercial planning for drugs/medicines still under development and for products already on the market.
The company says AI has helped reduce the time between the end of clinical trials and regulatory submissions by nearly two-thirds. This is the reason most pharmaceutical companies are betting on AI and trying to get more funding to improve the infra. Not only expansion, but it means a lot for the patients waiting for that “one drug” to cure their condition.
Novo Nordisk Bengaluru as the Emerging Hub
India’s role in this transformation is remarkable. Bengaluru’s Novo Nordisk office branch is now deeply involved in preparing medicines for launch across global markets.
“There’s no medicine that goes into market without having Bengaluru’s Thumbprint”, quotes John Dawber, managing director of global business services.
The company’s executives said that the large share of the work linked to international product launches is already being carried out from the India center. Reports claim that the Bengaluru team contributed extensively, including the recent launch of the oral obesity medicine in the US. This underscores India’s growing responsibilities, not just as a branch but as a functional center.
Competition in the Obesity Market
Novo Nordisk is known for its treatments for obesity and diabetes. While other competitors, such as Eli Lilly, are successfully launching new medicines and expanding their presence, the company is under pressure. This fuels the company’s investment in and development of AI in the drug discovery sector.
Increasing speed while reducing costs is the new approach companies are adopting. AI is becoming the backbone of today’s drug development system.
Plans for Hiring are Becoming More Selective
Novo Nordisk has no plans for a significant increase in hiring while continuing to expand its AI operations. The company reported that it expects its global business services workforce to be about 4,000 employees by the end of the current fiscal year (compared to previous estimates, which were higher).
According to Company Executives, this shift in hiring from a large to a selective workforce will continue, with hiring for specialist roles that support AI-based systems and enable scalable operational improvements in efficiency at lower operating costs, as well as faster drug launches.
Indication of the Digital Future of Pharma
Novo Nordisk’s most recent action is indicative of a growing trend across the drug manufacturing industry toward the digitalization of processes used to develop new and improved medicines, as well as to launch existing medicines in their current form.
The increasing use of AI technology in healthcare, regulatory science, data analysis, and pharmaceutical technology will provide additional opportunities in India. As companies continue to use AI methods to link research and development for pharmaceuticals and connected digital tools, the role of India will continue to expand internationally within the scope of global healthcare innovation.
